Lake Street Capital Lowers MiMedx Group (NASDAQ:MDXG) Price Target to $10.00

MiMedx Group (NASDAQ:MDXG) had its price objective decreased by equities researchers at Lake Street Capital from $12.00 to $10.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price objective would suggest a potential upside of 87.62% from the stock’s current price.

A number of other analysts also recently commented on MDXG. Mizuho dropped their target price on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Stock Down 1.1%

MDXG opened at $5.33 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The company has a market capitalization of $789.37 million, a PE ratio of 19.74 and a beta of 1.57. The stock’s fifty day moving average is $6.66 and its 200-day moving average is $6.89. MiMedx Group has a one year low of $5.13 and a one year high of $9.30.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The firm had revenue of $113.73 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities analysts predict that MiMedx Group will post 0.3 EPS for the current fiscal year.

Insider Activity at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total value of $432,586.00. Following the completion of the transaction, the insider owned 236,982 shares of the company’s stock, valued at approximately $1,758,406.44. This trade represents a 19.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.70% of the company’s stock.

Institutional Trading of MiMedx Group

A number of hedge funds have recently modified their holdings of the business. CWM LLC grew its holdings in shares of MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after buying an additional 1,892 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of MiMedx Group by 1,808.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after purchasing an additional 7,107 shares during the period. State of Alaska Department of Revenue purchased a new stake in shares of MiMedx Group in the third quarter worth approximately $54,000. Headlands Technologies LLC acquired a new stake in shares of MiMedx Group during the second quarter worth approximately $72,000. Finally, Osaic Holdings Inc. grew its position in MiMedx Group by 57.2% during the second quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock valued at $79,000 after purchasing an additional 4,708 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.